

Efficacy of ultramicrosized diclofenac in patients with osteoarthritis – systematic review with network meta-analysis

G.C. DE CAMPOS¹, E. DE ALMEIDA MACEDO², A.M. KUMMER²,
M. PAPALEO ROSIM³, M. MILLAN FACHI³, L.L. AULETTA²

¹Departamento de Ortopedia, Reumatologia e Traumatologia, Universidade Estadual de Campinas, Campinas, SP, Brazil

²Departamento Médico Científico, Grupo NC, Hortolândia, SP, Brazil

³Departamento de HEOR, MapeSolutions, São Paulo, SP, Brazil

Abstract. – OBJECTIVE: This systematic review with network meta-analysis was performed to compare the effectiveness of oral anti-inflammatory drugs used in Brazil for osteoarthritis.

PATIENTS AND METHODS: Randomized clinical trials evaluating ultramicrosized diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified. A search was conducted in May 2021 through PubMed, Scopus and Web of Science databases. A network meta-analysis was developed for efficacy outcome related to analgesia measured by the pain subscale of the Western Ontario and McMaster Universities tool. In addition, surface under the cumulative ranking was performed to rank the drugs in relation to this outcome.

RESULTS: Twelve randomized clinical trials were included. Overall, ultramicrosized diclofenac 105 mg/day (UD105) was better than all the others, including ultramicrosized diclofenac 70 mg/day (UD70). In addition, surface under the cumulative ranking resulted in the following order: 1) ultramicrosized diclofenac 105 mg/day (100%), 2) ultramicrosized diclofenac 70 mg/day (80%), 3) celecoxib 200 mg/day (49%), 4) diclofenac 100 mg/day (48%), 5) placebo (19%) and 6) diclofenac 150 mg/day (6%).

CONCLUSIONS: Ultramicrosized diclofenac demonstrated superior efficacy compared to other conventional anti-inflammatory drugs and placebo in relieving osteoarthritis pain.

Key Words:

Diclofenac, Celecoxib, Network meta-analysis, Osteoarthritis, Pain, Anti-inflammatory agents.

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most prescribed pharmacological

classes in the world, being widely used to treat a variety of pain conditions, especially in the context of osteoarticular diseases¹. Osteoarthritis (OA) is the most frequent joint disease in the world population, with prevalence of 10-15% in people aged over 60 years, with NSAIDs as one of the main therapeutic classes used in pain management related to this condition²⁻⁴.

Despite their widespread use, NSAIDs are associated with a risk of gastrointestinal, hepatic, cardiovascular and renal adverse events, some of which are potentially serious, such as gastrointestinal bleeding, acute myocardial infarction, and acute renal failure^{1,2,5,6}. The risk of occurrence of such adverse events presents a dose-dependent behaviour, with higher doses and longer treatment duration being related to greater toxicity. Thus, regulatory agencies such as the Food and Drug Administration (FDA) recommend NSAIDs to be used 'at the lowest effective dose, for the shortest possible duration necessary to achieve the treatment goals', in attempt to minimise the risk of complications⁷. On the other hand, simply reducing the dose of NSAIDs, although capable of increasing safety, may imply a lower analgesic and anti-inflammatory effect, potentially compromising effectiveness⁸.

Ultramicrosized diclofenac is a new nanoformulation of diclofenac, in which the drug particles are subjected to an ultramicrosization process, resulting in a final size 10-20 times smaller than conventional diclofenac particles. The considerable reduction in the average size of the particles allows for better dissolution of the drug and, consequently, greater absorption in the gastrointestinal tract, allowing the use of a lower dose without compromising therapeutic efficacy⁸.

Table I. Search strategy.

Databases	Search strategy
Pubmed 10.983	(((((((((diclofenac[Title/Abstract]) OR((solumatrix[Title/Abstract] AND diclofenac[Title/Abstract])) OR (bexai[Title/Abstract])) OR (celecoxib[Title/Abstract])) OR (celebra[Title/Abstract])) OR (etodolac[Title/Abstract])))) OR (diclofenac[MeSH Terms])) OR (Flancox[Title/Abstract])) AND Search (((((clinical[Title/Abstract]) AND trial[Title/Abstract]) OR 'clinical trials as topic'[MeSH Terms]) OR 'clinical trial'[Publication Type]) OR random*[Title/Abstract]) OR 'random allocation'[MeSH Terms]) OR 'therapeutic use'[MeSH Subheading])
Scopus 1.973	(TITLE-ABS(diclofenac OR (solumatrix AND diclofenac) OR bexai OR celecoxib OR celebra OR etodolac OR Flancox)) AND (TITLE-ABS((random AND trial) OR (clinical AND trial) OR 'clinical study'))
Web of science 2.412	((TÓPICO: ((((((diclofenac OR (solumatrix AND diclofenac)) OR bexai) OR celecoxib) OR celebra) OR etodolac) OR Flancox)) AND TÓPICO: (((random AND trial) OR (clinical AND trial)) OR 'clinical study'))

Note: Searches were conducted in May 2021.

The aim of this study was to comparatively evaluate, through a systematic literature review and network meta-analysis, the analgesic efficacy of ultramicronized diclofenac, sodium/potassium diclofenac, etodolac and celecoxib in the treatment of patients with OA.

Patients and Methods

All steps of this systematic review (SR) were conducted based on the guidelines of the *Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA)^{9,10} and recommendations of the *Cochrane Collaboration*¹¹.

Search Strategy and Eligibility

In order to compare the anti-inflammatory drugs: ultramicronized diclofenac, diclofenac, etodolac and celecoxib at different dosages commercially approved in Brazil, a search was performed in May 2021 through PubMed, Scopus and Web of Science databases. The search strategy for each database is presented in Table I. In addition, a manual search was performed through the reference list of the included studies and through grey-literature search.

After removing duplicates, two independent reviewers screened articles by evaluating titles and abstracts, and then read the selected articles in full. In cases of discrepancy, a third reviewer was also consulted. Randomised clinical trials (RCTs) that evaluated the effectiveness (analgesia) by the Western Ontario and McMaster Universities (WOMAC) pain subscale of at least two of the

proposed oral drugs (ultramicronized diclofenac, celecoxib, diclofenac, etodolac and placebo) at commercially available doses in Brazil in adult patients with OA (>18 years) requiring analgesic treatment were included in the SR.

Only studies in English, Portuguese and Spanish were included. Studies that addressed drug combination, subanalyses of other studies or post hoc analyses were excluded.

Data Extraction

Data extraction was performed using Excel software, extracting the following information from the included studies: study data (authors, year of publication and study center), baseline characteristics of the population (age, sample size) and outcome results of analgesia measured by the pain domain of the *Western Ontario and McMaster Universities* (WOMAC) instrument.

Statistical Analysis

For the comparison of interventions, a network meta-analysis (NMA) was performed, as this allows for the simultaneous direct and indirect comparison of medications. This statistical analysis is based on Bayesian methods, in which the Markov chain Monte Carlo simulation method (MCMC) is used to generate combined effect sizes¹²⁻¹⁵.

The results were expressed as mean difference (MD) in relation to the baseline and their respective 95% credible interval (CrI). Our final model adopted a random effect, as it is a more conservative analysis to explain the study variance. When necessary, subgroup and sensitivity analysis was performed considering the indications. To assess

whether there was a discrepancy between direct and indirect comparisons and to assess the strength of the network, an inconsistency and node split analysis was conducted¹⁶⁻¹⁸.

In addition, surface under the cumulative ranking (SUCRA) was performed to rank the probability that one drug was better than the other for the analgesia outcome. SUCRA values range from 0 to 100%. The higher the SUCRA value, and the closer to 100%, the higher the likelihood that a therapy is in the top rank or one of the top ranks; the closer to 0 the SUCRA value, the more likely a therapy is in the lower rank¹⁹. Analyses were conducted using the ADDIS software version 1.17.6 (Aggregate Data Drug Information System; <https://drugis.org/software/addis>)²⁰.

Bias Risk Assessment

To measure the risk of bias, the Cochrane tool (RoB 2.0) was used²¹. The following domains were evaluated: bias due to the randomization process, bias due to deviation from intended interventions, bias due to lack of outcome data, bias in outcome measurement and bias in the selection of reported outcomes. The risk of bias was judged in each domain as 'low risk', 'high risk' or with 'some concerns', being assessed by two independent reviewers; in cases of discrepancy a third reviewer was consulted.

Results

After excluding duplicates, 14,427 studies remained for the screening process. Then 14,248 studies were excluded, with 179 studies to be

read in full. Of these, 12 RCTs^{22,23,32,24-31} (n = 4,767 patients) were included for data extraction. The characteristics of the included studies are shown in Table II and the number of studies included in each step of this SR is shown in Figure 1.

As mentioned, the dosages of the medications evaluated are only those available in Brazil, and the nomenclature given to each comparator refers to the total daily quantity of medications. Thus, the following dosages were identified: celecoxib 200 mg (C200), diclofenac 150 mg (D150) and 100 mg (D100), and ultramicrosized diclofenac 105 mg (UD105) and 70 mg (UD70). No studies that met the established inclusion criteria were found to report the use of etodolac in patients with osteoarthritis.

The summary of the risk of bias assessment is presented in Table III. All studies had low overall risk of bias. Only a few studies showed 'some concerns' in the domain 'randomisation process' due to the lack of information about the randomisation process.

The NMA built for the outcome of analgesia efficacy measured by the pain subscale of the WOMAC tool is shown in Figure 2.

The NMA identified UD105 as superior to UD70 (MD 5.46; CrI 3.55-7.36), placebo (MD 12.45; CrI 10.62-14.38), D150 (MD 13.50; CrI 10.42-16.57), D100 (MD 10.78; CrI 7.47-14.13) and C200 (MD 11.05; CrI 8.91-13.05; Figure 3).

UD70 was statistically superior to C200 (MD 5.60; CrI 3.48-7.62), D100 (MD 5.35; CrI 1.93-8.71), D150 (MD 8.03; CrI 4.96-11.11) and placebo (MD 7.01; CrI 5.16-8.86; Figure 4).

Placebo proved to be less effective than C200 (MD -1.42; CrI -2.37 to -0.57; Figure 5), whereas

Table II. Main characteristics of the studies included in the systematic review.

Study	N	Treatment	Study design	Countries
Conaghan, 2013 ²²	463	C200, Placebo	RCT, double blind	Czech Republic, Germany, Poland and the UK
Essex, 2014 ²⁴	189	C200, Placebo	RCT, double blind	USA
Essex, 2016 ²³	223	C200, Placebo	RCT, double blind	USA
Fleischmann, 2005 ³³	678	C200, Placebo	RCT, double blind	Multicentric
Gibofsky, 2003 ²⁶	378	C200, Placebo	RCT, double blind, Phase 3	Multicentric (USA and Canada)
Gibofsky, 2014 ²⁵	304	UD 105, UD70, Placebo	RCT, double blind	Multicentric
Lee, 2017 ²⁷	216	C200, Placebo	RCT, double blind	South Korea
Lehmann, 2005 ²⁸	844	C200, Placebo	RCT, double blind	Multicentric
McKenna, 2001 ²⁹	600	C200, D150, Placebo	RCT, double blind	USA
Rother, 2007 ³⁰	259	C200, Placebo	RCT, double blind	Germany
Simon, 2009 ³¹	308	D100, Placebo	RCT, double blind	USA and Canada
Strand, 2017 ³²	305	UD105, UD70, Placebo	RCT, double blind, Phase 3	USA

Abbreviations: C200, celecoxib 200 mg; D150, diclofenac 150 mg; D100, diclofenac 100 mg; UD105, ultramicrosized diclofenac 105 mg; UD70, ultramicrosized diclofenac 70 mg.




Figure 1. Systematic review flowchart.

C200 was superior to D150 (MD 2.45; CrI 0.07-4.95). There was no statistical difference in the comparison between D100 and D150, (MD 2.73; CrI -1.06-6.36).

The SUCRA resulted in the following ranking: 1) UD105 (100%), 2) UD70 (80%), 3) C200 (49%), 4) D100 (48%), 5) Placebo (19%) and 6) D150 (6%; Table IV).

Sensitivity analyses were conducted for the study outcome, considering the different regimens and methodological quality. However, no additional differences were found in the original analyses (data not shown). The network was considered robust for the evaluated result. No substantial differences ($p > 0.05$) were identified through the inconsistency analysis. The node split

Table IV. SUCRA classification.

Rank	Treatment	SUCRA
1	UD105	100%
2	UD70	80%
3	C200	49%
4	D100	48%
5	Placebo	19%
6	D150	6%

Abbreviations: SUCRA, surface under the cumulative ranking; C200, celecoxib 200 mg; D150, diclofenac 150 mg; D100, diclofenac 100 mg; UD105, ultramicrosized diclofenac 105 mg; UD70, ultramicrosized diclofenac 70 mg; P, placebo.




Figure 2. Network meta-analysis for analgesia outcome. Abbreviations: C200, celecoxib 200 mg; D150, diclofenac 150 mg; D100, diclofenac 100 mg; UD105, ultramicrosized diclofenac 105 mg; UD70, ultramicrosized diclofenac 70 mg; P, placebo

analysis was not performed due to the lack of direct and indirect comparisons of two drugs.

Discussion

In this NMA comparing the analgesic efficacy of different anti-inflammatory drugs in patients




Figure 3. Forest plot comparing UD105 with other treatments. Abbreviations: MD, mean difference; C200, celecoxib 200 mg; D150, diclofenac 150 mg; D100, diclofenac 100 mg; UD105, ultramicrosised diclofenac 105 mg; UD70, ultramicrosised diclofenac 70 mg; P, placebo; CrI, credible interval.




Figure 4. Forest plot comparing UD70 with other treatments. Abbreviations: MD, mean difference; C200, 200 mg celecoxib; D100, 100 mg diclofenac; D150, 150 mg diclofenac; UD70, 70 mg ultramicrosised diclofenac; UD105, 105 mg ultramicrosised diclofenac; P, placebo; CrI, credible interval

with OA, ultramicrosised diclofenac proved to be the treatment option showing best results, both in comparison to placebo and to other active treatments. Ultramicrosised diclofenac in 35 mg presentation taken three times a day (UD105) or twice daily (UD70) showed better analgesia results compared to diclofenac and celecoxib. To the best of our knowledge, this is the first study to compare ultramicrosised diclofenac to other ac-

tive treatments in patients with OA, showing that low doses of ultramicrosised diclofenac are more effective in analgesia.

Two Phase 3 clinical trials evaluating ultramicrosised diclofenac were identified in the SR. Gibofsky et al²⁵ evaluated the efficacy of UD105 and UD70 for 12 weeks compared to placebo in controlling pain in patients with OA. In this study, 35 mg ultramicrosised diclofenac administered twice or three




Figure 5. Forest plot comparing placebo with other treatments. Abbreviations: MD, mean difference; C200, 200 mg celecoxib; D100, 100 mg diclofenac; D150, 150 mg diclofenac; UD70, 70 mg ultramicrosized diclofenac; UD105, 105 mg ultramicrosized diclofenac; P, placebo; CrI, credible interval.

times a day resulted in a statistically significant studies differs from other published works such as the meta-analysis by Costa et al (2017)³³.

Besides the efficacy data, the study by Gibofsky et al (2014)²⁵ evaluated the safety profile of ultramicrosized diclofenac, noting that none of the patients had ulcers, gastrointestinal bleeding or perforation, myocardial infarction, stroke or renal failure, and a small number of patients had to discontinue the treatment. Furthermore, an open study was conducted to analyze the use of ultramicrosized diclofenac in 601 patients with OA for a period of up to 52 weeks. This study demonstrated that treatment was well tolerated and associated with improved quality-of-life measures, with only 16.5% of patients discontinuing treatment. Serious gastrointestinal, cardiovascular, renal and hepatic adverse events were uncommon³⁴.

The impossibility of performing a safety analysis of ultramicrosized diclofenac in comparison to other active treatments was the main limitation of this meta-analysis. This was because only a few of the adverse events reported in the ultramicrosized diclofenac studies were reported for other treatments, preventing the formation of an NMA for specific adverse events. Nevertheless, safety is probably one of the great advantages of ultramicrosized diclofenac when compared to traditional diclofenac or other NSAIDs with conventional formulation. This is related to particle size reduction and consequent increase in surface area promotes

increased bioavailability, making it possible to achieve analgesia with lower doses, decrease systemic exposure³⁵ and thus minimize the frequency and severity of adverse events while maintaining efficacy. Considering that patients with OA make chronic use of NSAIDs, further studies analysing the long-term effects of ultramicrosized diclofenac would be of great interest. New safety and efficacy studies making direct comparisons between ultramicrosized diclofenac and conventional NSAIDs are needed to assess this potential.

Conclusions

In this analysis, patients with osteoarthritis had greater pain relief through the use of ultramicrosized diclofenac when compared to those who used conventional anti-inflammatory drugs or placebo.

Conflict of Interest

All authors work or received fees from a company, however this did not compromise the analysis.

Disclosure

GCC received a fee from NC Group as consulting fee. EAM was a full-time employee of NC Group during the development of this manuscript. LLA and AMK are full-time employees of NC Group. MPR and MMF are employees of a consultancy company hired by NC Group.

Author Declarations of Individual Contributions

GCC contributed to study concept, study design, data collection, data interpretation and writing of the manuscript. EAM contributed to study concept, study design, data interpretation and writing of the manuscript. AMK contributed to study design, data interpretation and writing and reviewing of the manuscript. MPR contributed to data collection, data analysis, data interpretation and writing of the manuscript. MMF contributed to data collection, data analysis, data interpretation and writing of the manuscript. LLA contributed to study concept, study design and reviewing of the manuscript.

References

- 1) Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. *Biochem Pharmacol* 2020; 180: 1-26.
- 2) Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, Goldring SR, Jones G, Teichtahl AJ, Pelletier JP. Osteoarthritis. Vol. 2, *Nat Rev Dis Primers* 2016; 2: 1-18.
- 3) Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. *Lancet* 2015; 386: 376-387.
- 4) Vincent TL, Watt FE. Osteoarthritis *Med (United Kingdom)* 2018; 187-195.
- 5) Pereira-Leite C, Nunes C, Jamal SK, Cuccovia IM, Reis S. Nonsteroidal Anti-Inflammatory Therapy: A Journey Toward Safety. *Med Res Rev* 2017; 37: 802-809.
- 6) Cooper C, Chapurlat R, Al-Daghri N, Herro-Beaumont G, Bruyère O, Rannou F, Roth R, Uebelhart D, Reginster JY. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? *Drugs Aging* 2019; 36: 15-24.
- 7) US Food and Drug Administration. Public Health Advisory—FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety>.
- 8) Manvelian G, Daniels S, Gibofsky A. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. *Postgrad Med* 2012; 124: 117-123.
- 9) Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. *Ann Intern Med* 2015; 162: 777-784.
- 10) Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6: 1-6.
- 11) Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0. 2011.
- 12) Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. *Pharm Pract* 2017; 15: 943-943.
- 13) Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. *BMC Med* 2013; 11: 1-8.
- 14) Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. *Value Heal* 2011; 14: 429-437.
- 15) Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. *Value Heal* 2011; 14: 417-428.
- 16) Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016; 7: 80-93.
- 17) Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* 2010; 29: 932-944.
- 18) Veroniki AA, Vasiladis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. *Int J Epidemiol* 2013; 42: 332-345.
- 19) Mbuagbaw L, Rochweg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, Guyatt GH. Approaches to interpreting and choosing the best treatments in network meta-analyses. *Syst Rev* 2017; 6: 1-5.
- 20) van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. *Res Synth Methods* 2012; 3: 285-299.
- 21) Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reever BC, Sherpherd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; 366: 1-8.
- 22) Conaghan PG, Dickson J, Bolten W, Cevc G, Rother M. A multicentre, randomized, placebo and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. *Rheumatology* 2013; 52: 1303-1312.
- 23) Essex MN, O'Connell MA, Behar R, Bao W. Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis:

- summary of a randomised, placebo-controlled study. *Int J Rheum Dis* 2016; 19: 262-270.
- 24) Essex MN, Behar R, Bhadra Brown P, O'Connell M. Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis. *Int J Gen Med* 2014; 227-235.
- 25) Gibofsky A, Hochberg MC, Jaros MJ, Young CL. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12-week, Phase 3 study. *Curr Med Res Opin* 2014; 30: 1883-1893.
- 26) Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo-controlled trial. *Arthritis Rheum* 2003; 48: 3102-3111.
- 27) Lee M, Yoo J, Kim JG, Kyung H-S, Bin S-I, Kang SB, Choi CH, Moon YW, Kim YM, Han SB, In Y, Choi CH, Kim J, Lee BK, Cho S. A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis. *Clin Orthop Surg* 2017; 9: 439-457.
- 28) Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreiss A, Thurston H, Litschig S, Sloan VS. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. *Curr Med Res Opin* 2005; 21: 517-526.
- 29) F. McKenna, D. Borenstein HW. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison. *Scand J Rheumatol* 2001; 30: 11-18.
- 30) Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. *Ann Rheum Dis* 2007; 66: 1178-1183.
- 31) Simon LS, Grierson LM, Naseer Z, Bookman AAM, Shainhouse ZJ. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. *Pain* 2009; 143: 238-245.
- 32) Strand V, Bergman M, Singh JA, Gibofsky A, Kivitz A, Young C. Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial. *Clin Rheumatol* 2017; 36: 1357-1367.
- 33) da Costa BR, Reichenbach S, Keller N, Narthey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet* 2017; 390: e21-e33.
- 34) Altman RD, Strand V, Hochberg MC, Gibofsky A, Markenson JA, Hopkins WE, Cryer B, Kivitz A, Nezzar J, Imasogie O, Young CL. Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study. *Postgrad Med* 2015; 127: 517-528.